GERMANTOWN, Md., Aug. 3, 2023
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a
biopharmaceutical company specializing in the development of
innovative gene and cell therapies to improve the lives of
patients, today announced the Company will release second quarter
and first half 2023 financial results on Wednesday, August 9, 2023. The Company will host
a conference call that day at 8:30 AM
ET to discuss financial results and provide a general
business update.
The conference call may be accessed by dialing 1-888-317-6003
(Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and
providing the participant access code 7000413. Participants are
asked to dial in 10-15 minutes in advance of the scheduled call
time to facilitate timely connection to the call.
Event details can be found on Precigen's website in the Events
& Presentations section at
investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with
Precision™
Precigen (Nasdaq: PGEN) is a
dedicated discovery and clinical stage biopharmaceutical company
advancing the next generation of gene and cell therapies using
precision technology to target the most urgent and intractable
diseases in our core therapeutic areas of immuno-oncology,
autoimmune disorders, and infectious diseases. Our technologies
enable us to find innovative solutions for affordable
biotherapeutics in a controlled manner. Precigen operates as an
innovation engine progressing a preclinical and clinical pipeline
of well-differentiated therapies toward clinical proof-of-concept
and commercialization. For more information about Precigen, visit
www.precigen.com or follow us on Twitter @Precigen, LinkedIn
or YouTube.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press
release are forward-looking statements. These forward-looking
statements are based upon the Company's current expectations and
projections about future events and generally relate to plans,
objectives, and expectations for the development of the Company's
business, including the timing and progress of preclinical studies,
clinical trials, discovery programs and related milestones, the
promise of the Company's portfolio of therapies, and in particular
its CAR-T and AdenoVerse therapies. Although management believes
that the plans and objectives reflected in or suggested by these
forward-looking statements are reasonable, all forward-looking
statements involve risks and uncertainties and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release. The Company has no
obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. For further information on potential risks
and uncertainties, and other important factors, any of which could
cause the Company's actual results to differ from those contained
in the forward-looking statements, see the section entitled "Risk
Factors" in the Company's most recent Annual Report on Form 10-K
and subsequent reports filed with the Securities and Exchange
Commission.
Investor Contact:
Steven M.
Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M.
Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-to-announce-second-quarter-and-first-half-2023-financial-results-on-august-9th-301893048.html
SOURCE Precigen, Inc.